Loading

European Union · Global Market Access

Entering the EU Market: In Vitro Diagnostic Devices (IVDR)

In Vitro Diagnostic Regulation — classification is rule-based, most devices fall under NB scope.

Market
European Union
Site
European
Mark
IVDR

01What is it?

The In Vitro Diagnostic Medical Devices Regulation governs diagnostic tests and the related devices. Its greatest difference from the earlier directive is that classification has moved from a list basis to a rule basis, and as a result most devices have come within the scope of a notified body.

02Why Does This Scheme Exist?

The change brought by the in vitro diagnostic devices regulation is more fundamental than that on the medical device side, and the reason is that risk classification has been rebuilt entirely. Under the old regime diagnostic kits could as a rule reach the market on manufacturer declaration, and only a short list was subject to third-party assessment.

The new regulation inverted that logic: devices were divided into four classes according to the effect of the result they give on the patient and on public health, and the majority came within the scope of a notified body. Because a wrong result from a diagnostic test leads directly to the wrong treatment, this is a coherent change in regulatory logic.

The classification rules look not at the device itself but at its INTENDED PURPOSE: two kits measuring the same analyte can fall into different classes when one is declared for screening and the other for confirmation. The statement of intended purpose is therefore the most critical text of the regulation.

On the evidence side, performance evaluation has become central: analytical performance (sensitivity, specificity, trueness, interference effects) and clinical performance are demonstrated separately and the performance evaluation report forms the core of the technical file.

The regulation also establishes a special arrangement for tests produced by health institutions in-house, and this ties laboratories' own developed methods to a clear framework for the first time. The transition periods were graded by class and extended several times because of capacity bottlenecks.

03Whose Obligation?

The obligation lies with the manufacturer; for manufacturers outside the EU an authorised representative established in the EU is mandatory. A PRRC must be appointed.

04Required Documents

  • The device description, intended purpose and classification rationale
  • Analytical performance data
  • Clinical performance and scientific-validity evidence
  • Stability and shelf-life studies
  • The risk management file
  • ISO 13485 quality management system records
  • UDI information and EUDAMED registration

05Process

  1. 01Scope DeterminationIt is determined which legislation and marking scope the product falls under in the target market. This step defines the entire process; getting it wrong wastes all subsequent work.
  2. 02Determining Applicable StandardsThe standards accepted by the market and any national deviations are identified. The same IEC standard may apply with different deviations in different markets.
  3. 03Establishing the Test PlanIt is assessed which part of existing test reports will be accepted; missing tests are planned. A CB Scheme report, if available, reduces retesting.
  4. 04Local Party and RegistrationIf the market requires an established representative, importer or applicant, this party is designated and the necessary registrations are made.
  5. 05Tests and Technical FileTests are conducted and the technical file is prepared. Some markets require testing to be performed within their own country.
  6. 06Certification or DeclarationDepending on the market's regime, a manufacturer's declaration is drawn up or a certificate is obtained from the authorised body; a factory audit is carried out if required.
  7. 07Marking and LabellingThe mark and label are applied according to the market's format and language rules. The language requirement is checked at customs in most markets.
  8. 08Shipment and CustomsIf a pre-shipment document is required, it is obtained; the document set to be presented at customs is completed.

06Points to Watch

  • For sterile Class A and for Class B, C and D devices a notified body is involved
  • For Class D, an EU reference laboratory and batch verification come into play
  • Most devices that reached the market on self-declaration under the old directive are now within the scope of a notified body
  • There is a conditional exemption for tests produced within a health institution

07Neighbouring Schemes and the Difference

  1. 01IVDR and MDRThe MDR covers devices acting directly on the patient, the IVDR devices making measurements on a specimen. Their classification logics and forms of evidence differ; a kit cannot be assessed under the MDR.
  2. 02IVDR and laboratory accreditationISO 15189 qualifies the competence of a medical laboratory; the IVDR governs the conformity of the KIT the laboratory uses. The two assess different subjects.
  3. 03IVDR and in-house produced testsThere is a separate arrangement for tests a health institution produces in-house and uses only on its own patients; this is a conditional exception rather than a full exemption.
  4. 04IVDR and instrument standardsIEC 61010 addresses the electrical safety of a laboratory instrument; the IVDR looks for the reliability and clinical performance of the diagnostic result. Instrument safety is only one part of an IVDR file.

08Scheme Detail

This page describes entry into the European Union market. The scheme itself — its scope, process, validity period and required documents — is covered in detail on the certification page.

In Vitro Diagnostic Devices Directive (IVDR) and CE Marking

09Other Marks in the European Union Market

10Frequently Asked Questions

This section's content is being prepared. The roadmap specific to your product and target market at the quote stage in writing.

The certification timeline varies with the product, the required test workload, sample shipping time and the authority's workload; for this reason, no duration in days or weeks is given on these pages. The main factors determining the timeline are: whether testing must be performed in the target country, whether a factory audit is required, the time to appoint a local representative, and the current maturity of the technical file. A realistic timeline for your product is provided in writing at the quote stage.

Market access regimes change frequently: scope lists are updated, transition periods are extended, new requirements are added. These pages describe the structure of the regime and who bears the obligation; the applicable scope and dates for your product are confirmed from the current legislative text at the quote stage.

European Union · IVDR roadmap for

Tell us about your product; we'll share the required steps, documents and timeline in writing.

We use cookies required for the site to work. With your permission we also add an analytics cookie to understand how pages are used. Cookie Policy